Efficacy News and Research

RSS

PP&AR: 1 out of 4 older Americans experience unwanted medical treatment

Nearly one out of four older Americans say that either they or a family member have experienced excessive or unwanted medical treatment, according to the latest issue of The Gerontological Society of America's Public Policy & Aging Report, which goes on to show that Americans strongly support holding doctors accountable when they fail to honor patients' end-of-life health care wishes.

31 Oct 2014

Family therapy useful in bipolar disorder

Psychoeducational family intervention improves social functioning in patients with bipolar I disorder and reduces burden among close relatives, Italian study data show.

31 Oct 2014

Researchers develop new technique to create cellular scaffolding for tissue engineering

Researchers at the University of Washington have developed a way to use sound to create cellular scaffolding for tissue engineering, a unique approach that could help overcome one of regenerative medicine's significant obstacles.

31 Oct 2014

Men with BPH need to discuss 'male orgasmic dysfunction' with doctors prior to any treatment

NeoTract, Inc., today welcomes the publication of a paper in the British Journal of Urology International which calls for men suffering from enlarged prostate to discuss with their doctors the likely impact of treatment options on their sexual function. Most procedures and many medications can cause sexual dysfunction. Clinical studies show that treatment with the UroLift system has not been associated with any new onset of sustained ejaculatory or erectile dysfunction.

31 Oct 2014

Dosing of antiretroviral medication to prevent HIV infection differs by sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex.

31 Oct 2014

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).

30 Oct 2014

Quality of life maintained during mRCC TKI therapy

Treatment with tyrosine kinase inhibitors does not appear to significantly impair health-related quality of life in Japanese patients with metastatic renal cell carcinoma, say researchers.

30 Oct 2014

Insufficient Th1 polarisation blocks RCC vaccine efficacy

A lack of a clinical response to an allogenic gene-modified renal cell cancer vaccine may be due to insufficient type 1 T-helper cell polarisation, show results of a gene expression profiling study.

30 Oct 2014

TNF-α key player in RCC progression

Tumour necrosis factor - α appears to play a key role in the promotion of invasion and metastasis in clear cell renal cell carcinomas, Japanese study findings indicate.

30 Oct 2014

EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

Epidermal growth factor receptor–tyrosine kinase inhibitors appear to significantly reduce the efficacy of subsequent chemotherapy in patients with EGFR-mutated non-small-cell lung cancer, Chinese researchers report.

30 Oct 2014

Research shows that copper could help to prevent Ebola spread

Research from the University of Southampton has indicated that copper could help to prevent the spread of Ebola.

30 Oct 2014

EndoChoice study supports Fuse Full Spectrum Endoscopy System

EndoChoice announced the release of study data supporting the efficacy of the Fuse Full Spectrum Endoscopy System. These studies were presented simultaneously by leading gastroenterologists at the American College of Gastroenterology Annual Scientific Session in Philadelphia, PA, and the United European Gastroenterology Week in Vienna, Austria.

30 Oct 2014

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014.

30 Oct 2014

NCI supports further clinical development of next-generation HPV vaccine

The National Cancer Institute in the USA is supporting the new vaccine developed at the MedUni Vienna against the human papillomavirus (HPV) with at least US$ 3.5 million. This is a major success for the developers and means that the foundations can now be laid for the clinical trials needed for licensing as a vaccine.

30 Oct 2014

FIT screening may be as effective as colonoscopy in detecting familial colorectal cancer

Fecal immunochemical tests (FIT) may be as effective as colonoscopies when it comes to detecting colorectal cancer among first-degree relatives of patients with colorectal cancer, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

30 Oct 2014

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

The uncontrolled growth of cancer cells arises from their ability to hijack the cell’s normal growth program and checkpoints. Usually after therapy, a second cancer-signaling pathway will open after the primary one shuts down — creating an ingenious escape route for the cancer cell to survive. The answer, say Case Western Reserve researchers, is to anticipate and block that back-up track by prescribing two drugs from the start.

29 Oct 2014

Osteros Biomedica initiates MBC-11 phase 1 study in patients with cancer-induced bone disease

Osteros Biomedica Ltd., a joint venture company of Maxwell Biotech Group and MBC Pharma Inc., and formed with the participation of Russian Venture Company announced today that the first cohort of patients has been dosed in a phase 1 study of its drug MBC-11 in patients with cancer-induced bone disease.

28 Oct 2014

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.

28 Oct 2014

ETEC vaccine candidate provides significant protection against bacterial diarrhea

New results from a safety and immunogenicity study, which included a challenge phase to test efficacy, indicate that a live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine candidate, given in combination with a novel adjuvant, provided significant protection against disease.

28 Oct 2014

RPC1063 drug candidate has potential to improve treatment for ulcerative colitis patients

Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute.

28 Oct 2014

Efficacy News and Research

PP&AR: 1 out of 4 older Americans experience unwanted medical treatment

Family therapy useful in bipolar disorder

Researchers develop new technique to create cellular scaffolding for tissue engineering

Men with BPH need to discuss 'male orgasmic dysfunction' with doctors prior to any treatment

Dosing of antiretroviral medication to prevent HIV infection differs by sex

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Quality of life maintained during mRCC TKI therapy

Insufficient Th1 polarisation blocks RCC vaccine efficacy

TNF-α key player in RCC progression

EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

Research shows that copper could help to prevent Ebola spread

EndoChoice study supports Fuse Full Spectrum Endoscopy System

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

NCI supports further clinical development of next-generation HPV vaccine

FIT screening may be as effective as colonoscopy in detecting familial colorectal cancer

Rapamycin and dasatinib combination may be beneficial in treating breast cancer, say scientists

Osteros Biomedica initiates MBC-11 phase 1 study in patients with cancer-induced bone disease

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

ETEC vaccine candidate provides significant protection against bacterial diarrhea

RPC1063 drug candidate has potential to improve treatment for ulcerative colitis patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News